Healthcare

UK commission proposes lifecycle regulation for healthcare AI

A UK commission recommended staged authorization, post-market monitoring, sandboxes, and clearer liability for AI-enabled medical devices.

The UK’s National Commission into the Regulation of AI in Healthcare reportedly recommended a lifecycle-based framework for AI-enabled medical devices. Its recommendations included staged authorization, continuous real-world monitoring, regulatory sandboxes, clearer liability rules, and regular performance reporting. The proposed model would place greater emphasis on post-market surveillance where complete pre-market assessment is difficult. This approach reflects the adaptive nature of many AI systems, which can change through updates or behave differently across clinical environments. The development matters because conventional medical-device approval processes may not fully address continuously updated software. Lifecycle oversight could give regulators and providers a way to monitor performance after deployment while preserving access to useful tools. Clearer responsibilities may also help hospitals determine how vendors and clinical users should respond when systems fail or drift.

Original source: Fægre Drinker Biddle & Reath

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI